# Roche to acquire LumiraDx's Point of Care technology

Roche announced a definitive agreement to acquire select parts of the LumiraDx group related to its Point of Care technology for a purchase price of USD 295 million plus up to USD 55 million. The transaction is expected to close by mid-2024.

- Type: Acquisition
- Announced: 2023-12-29
- Where: Switzerland
- Value: $295.0M
- Status: announced
- Products: Point of Care diagnostic technology, immunoassay tests, clinical chemistry tests
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Roche Holdings Inc](https://endata.com/companies/16415.md) (acquirer)
- [LumiraDx](https://endata.com/companies/74713.md) (target)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2023/12/29/2802173/0/en/roche-enters-into-a-definitive-agreement-to-acquire-lumiradx-s-point-of-care-technology-combining-multiple-diagnostic-modalities-on-a-single-platform.html), 2023-12-29: "Roche announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.